<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2026.655</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-2801</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ОRIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group></article-categories><title-group><article-title>Antenatal magnesium sulfate (MgSO4) regimens for neuroprotection in preterm neonates</article-title><trans-title-group xml:lang="ru"><trans-title>Схемы применения сульфата магния (MgSO4) в антенатальный период для нейропротекции у недоношенных новорожденных</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эльмасри</surname><given-names>Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Elmasry</surname><given-names>Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Эльмасри Ясмин, MD.</p><p>31527 Танта, улица Аль-Гейш</p></bio><bio xml:lang="en"><p>Yasmin Elmasry, MD.</p><p>Al-Geish Str., Tanta 31527</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мохаммед</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mohamed</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мохамед Ашраф, MD.</p><p>31527 Танта, улица Аль-Гейш</p></bio><bio xml:lang="en"><p>Ashraf Mohamed, MD.</p><p>Al-Geish Str., Tanta 31527</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4389-2347</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эльсокари</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Elsokary</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Эльсокари Амаль, MD.</p><p>31527 Танта, улица Аль-Гейш</p></bio><bio xml:lang="en"><p>Amal Elsokary, MD.</p><p>Al-Geish Str., Tanta 31527</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8910-3465</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эльшвайх</surname><given-names>Ш.Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Elshwaikh</surname><given-names>Sh. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Эльшвайх Шериф Лофти, MD.</p><p>31527 Танта, улица Аль-Гейш</p></bio><bio xml:lang="en"><p>Shereef Lofty Elshwaikh, MD.</p><p>Al-Geish Str., Tanta 31527</p></bio><email xlink:type="simple">frommetou35@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Университет Танта</institution><country>Египет</country></aff><aff xml:lang="en"><institution>Tanta University</institution><country>Egypt</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>10</day><month>05</month><year>2026</year></pub-date><volume>20</volume><issue>2</issue><fpage>271</fpage><lpage>280</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Elmasry Y., Mohamed A., Elsokary A., Elshwaikh S., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Эльмасри Я., Мохаммед А., Эльсокари А., Эльшвайх Ш.</copyright-holder><copyright-holder xml:lang="en">Elmasry Y., Mohamed A., Elsokary A., Elshwaikh S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/2801">https://www.gynecology.su/jour/article/view/2801</self-uri><abstract><sec><title>Aim</title><p>Aim: to assess the comparative effectiveness and adverse effects of different magnesium sulfate (MgSO4) regimens for fetus neuroprotection in women who are considered at risk of preterm birth.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. This randomized controlled clinical single-center study was taken place at the Obstetrics and Gynecology Department of Tanta University Hospital, a tertiary care referral center and neonatology department. The research was carried on pregnant female with gestational age 24–34 weeks with established preterm labor. The patients were sorted into four groups at random. Number of cases in each group was 20 cases, and they were assigned to one of the four groups using a computer-based program. All groups of women had received care in accordance with accepted clinical standards. Throughout the infusion, the protocol required that the mother's heart rate, blood pressure, breathing rate, tendon reflexes, and any negative effects be recorded. Throughout labor, the fetal heart rate had been checked. Mothers and their newborns were monitored until they were released from the hospital.</p></sec><sec><title>Results</title><p>Results. There are different regimens for its use, and there was no difference between all the regimens in its effect for neuroprotection either clinically or radiologically or in its safety, so we recommend the use of the least dose (loading dose 4 g over 30 minutes) to decrease the risk of side effects.</p></sec><sec><title>Conclusion</title><p>Conclusion. It is recommended to use MgSO4 for neuroprotection as it is a safe feasible effective and efficient method as well as it can prevent the trans cranial ultrasound positive findings for encephalopathy. MgSO4 prevents cerebral palsy by age 2, but its effect on cognition and behavior at school age remains uncertain and warrants further study.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель: оценить сравнительную эффективность и побочные эффекты различных схем приема сульфата магния (MgSO4) для нейропротекции плода у женщин, подверженных риску преждевременных родов.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Настоящее рандомизированное контролируемое клиническое одноцентровое исследование длительностью около 9 месяцев проводилось в отделении акушерства и гинекологии больницы университета Танта, специализированном центре третичной медицинской помощи и отделении неонатологии. В исследование вошли беременные со сроком гестации 24–34 недели с начавшимися преждевременными родами, случайным образом разделенные на 4 группы по 20 женщин, получавших медицинскую помощь в соответствии с принятыми клиническими стандартами. Во время инфузии сульфата магния (MgSO4) по протоколу оценивали частоту сердечных сокращений матери, кровяное давление, частоту дыхания, сухожильные рефлексы и любые негативные эффекты. Сердечный ритм плода измеряли во время родов. Матери и их новорожденные находились под наблюдением до выписки из больницы.</p></sec><sec><title>Результаты</title><p>Результаты. Существуют различные режимы применения препарата сульфата магния (MgSO4), для которых в ходе исследования не выявлено различий по нейропротективному эффекту в клинических проявлениях, рентгенологических признаках, а также в профиле безопасности. На основании этого для снижения риска побочных эффектов рекомендуется использовать минимальную дозу (нагрузочная доза 4 г в течение 30 минут).</p></sec><sec><title>Заключение</title><p>Заключение. Рекомендуется использовать сульфат магния (MgSO4) для нейропротекции, поскольку это безопасный, эффективный и доступный метод, способный предотвратить появление признаков энцефалопатии при транскраниальном ультразвуковом исследовании. Сульфат магния (MgSO4) предотвращает церебральный паралич к двухлетнему возрасту пациентов, но его влияние на когнитивные и поведенческие показатели в школьном возрасте остается неопределенным и требует дальнейшего изучения.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сульфат магния</kwd><kwd>MgSO4</kwd><kwd>нейропротекция</kwd><kwd>преждевременные роды</kwd></kwd-group><kwd-group xml:lang="en"><kwd>magnesium sulfate</kwd><kwd>MgSO4</kwd><kwd>neuroprotection</kwd><kwd>preterm birth</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Conde-Agudelo A., Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks ’gestation: a systematic review and meta-analysis. Am J Obstet Gynecol. 2009;200(6):595–609. https://doi.org/10.1016/j.ajog.2009.04.005.</mixed-citation><mixed-citation xml:lang="en">Conde-Agudelo A., Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks ’gestation: a systematic review and meta-analysis. Am J Obstet Gynecol. 2009;200(6):595–609. https://doi.org/10.1016/j.ajog.2009.04.005.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rouse D. Magnesium sulfate for the prevention of cerebral palsy. Am J Obstet Gynecol. 2009;200(6):610–2. https://doi.org/10.1016/j.ajog.2009.04.004.</mixed-citation><mixed-citation xml:lang="en">Rouse D. Magnesium sulfate for the prevention of cerebral palsy. Am J Obstet Gynecol. 2009;200(6):610–2. https://doi.org/10.1016/j.ajog.2009.04.004.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hutchison H.T., Nichols M.M., Kuhn C.R., Vaisaka A. Effects of magnesium sulfate on uterine contractility, intrauterine fetus, and infant. Am J Obstet Gynecol. 1964;88:747–58. https://doi.org/10.1016/0002-9378(64)90608-8.</mixed-citation><mixed-citation xml:lang="en">Hutchison H.T., Nichols M.M., Kuhn C.R., Vaisaka A. Effects of magnesium sulfate on uterine contractility, intrauterine fetus, and infant. Am J Obstet Gynecol. 1964;88:747–58. https://doi.org/10.1016/0002-9378(64)90608-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safetycommunication-fda-recommends-against-prolonged-use-magnesiumsulfate-stop-pre-term. [Accessed: 15.05.2025].</mixed-citation><mixed-citation xml:lang="en">FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safetycommunication-fda-recommends-against-prolonged-use-magnesiumsulfate-stop-pre-term. [Accessed: 15.05.2025].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Magnesium sulfate use in obstetrics. Committee Opinion No. 652. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2016;127:e52–3. https://doi.org/10.1097/AOG.0000000000001267.</mixed-citation><mixed-citation xml:lang="en">Magnesium sulfate use in obstetrics. Committee Opinion No. 652. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2016;127:e52–3. https://doi.org/10.1097/AOG.0000000000001267.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Crowther C.A., Middleton P.F., Voysey M. et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLoS Med. 2017;14(10):e1002398. https://doi.org/10.1371/journal.pmed.1002398.</mixed-citation><mixed-citation xml:lang="en">Crowther C.A., Middleton P.F., Voysey M. et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLoS Med. 2017;14(10):e1002398. https://doi.org/10.1371/journal.pmed.1002398.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine. Committee Opinion No. 573: Magnesium sulfate use in obstetrics. Obstet Gynecol. 2013;122(3):727–8. https://doi.org/10.1097/01.AOG.0000433994.46087.85.</mixed-citation><mixed-citation xml:lang="en">American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine. Committee Opinion No. 573: Magnesium sulfate use in obstetrics. Obstet Gynecol. 2013;122(3):727–8. https://doi.org/10.1097/01.AOG.0000433994.46087.85.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shennan A., Suff N., Jacobsson B; on behalf of the FIGO Working Group for Preterm Birth. FIGO good practice recommendations on magnesium sulfate administration for preterm fetal neuroprotection. Int J Gynecol Obstet. 2021;155(1):31–3. https://doi.org/10.1002/ijgo.13856.</mixed-citation><mixed-citation xml:lang="en">Shennan A., Suff N., Jacobsson B; on behalf of the FIGO Working Group for Preterm Birth. FIGO good practice recommendations on magnesium sulfate administration for preterm fetal neuroprotection. Int J Gynecol Obstet. 2021;155(1):31–3. https://doi.org/10.1002/ijgo.13856.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Crowther C.A., Hiller J.E., Doyle L.W., Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA. 2003;290(20):2669–76. https://doi.org/10.1001/jama.290.20.2669.</mixed-citation><mixed-citation xml:lang="en">Crowther C.A., Hiller J.E., Doyle L.W., Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA. 2003;290(20):2669–76. https://doi.org/10.1001/jama.290.20.2669.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomized trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG. 2007;114(3):289–99. https://doi.org/10.1111/j.1471-0528.2006.01165.x.</mixed-citation><mixed-citation xml:lang="en">Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomized trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG. 2007;114(3):289–99. https://doi.org/10.1111/j.1471-0528.2006.01165.x.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Marret S., Marpeau L., Zupan-Simunek V. et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomized controlled PREMAG trial. BJOG. 2007;114(3):310–8. https://doi.org/10.1111/j.1471-0528.2006.01162.x.</mixed-citation><mixed-citation xml:lang="en">Marret S., Marpeau L., Zupan-Simunek V. et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomized controlled PREMAG trial. BJOG. 2007;114(3):310–8. https://doi.org/10.1111/j.1471-0528.2006.01162.x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rouse D.J., Hertz D.G., Thom E. et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359(9):895–905. https://doi.org/10.1056/NEJMoa0801187.</mixed-citation><mixed-citation xml:lang="en">Rouse D.J., Hertz D.G., Thom E. et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359(9):895–905. https://doi.org/10.1056/NEJMoa0801187.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child: National Clinical Practice Guidelines. Adelaide: The University of Adelaide, 2010. 140 p.</mixed-citation><mixed-citation xml:lang="en">The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child: National Clinical Practice Guidelines. Adelaide: The University of Adelaide, 2010. 140 p.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Magee L., Sawchuck D., Synnes A., von Dadelszen P. Magnesium sulphate for Fetal Neuroprotection Consensus Committee. Maternal Fetal Medicine Committee. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J Obstet Gynecol Can. 2011;33(5):516– 29. https://doi.org/10.1016/S1701-2163(16)34886-1.</mixed-citation><mixed-citation xml:lang="en">Magee L., Sawchuck D., Synnes A., von Dadelszen P. Magnesium sulphate for Fetal Neuroprotection Consensus Committee. Maternal Fetal Medicine Committee. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J Obstet Gynecol Can. 2011;33(5):516– 29. https://doi.org/10.1016/S1701-2163(16)34886-1.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Reeves S.A., Gibbs R.S., Clark S.L. Magnesium for fetal neuroprotection. Am J Obstet Gynecol. 2011;204(3):202.e1–4. https://doi.org/10.1016/j.ajog.2011.01.014.</mixed-citation><mixed-citation xml:lang="en">Reeves S.A., Gibbs R.S., Clark S.L. Magnesium for fetal neuroprotection. Am J Obstet Gynecol. 2011;204(3):202.e1–4. https://doi.org/10.1016/j.ajog.2011.01.014.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Vacanti F.X., Ames A. Mild hypothermia and Mg++ protect against irreversible damage during CNS ischemia. Stroke. 1984;15(4):695–8. https://doi.org/10.1161/01.str.15.4.695.</mixed-citation><mixed-citation xml:lang="en">Vacanti F.X., Ames A. Mild hypothermia and Mg++ protect against irreversible damage during CNS ischemia. Stroke. 1984;15(4):695–8. https://doi.org/10.1161/01.str.15.4.695.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Clark G.D., Rothman S.M. Blockade of excitatory amino acid receptors protects anoxic hippocampal slices. Neuroscience. 1987;21(3):665–71. https://doi.org/10.1016/0306-4522(87)90027-3.</mixed-citation><mixed-citation xml:lang="en">Clark G.D., Rothman S.M. Blockade of excitatory amino acid receptors protects anoxic hippocampal slices. Neuroscience. 1987;21(3):665–71. https://doi.org/10.1016/0306-4522(87)90027-3.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">McIntosh T.K., Vink R., Yamakami I., Faden A.I. Magnesium protects against neurological deficit after brain injury. Brain Res. 1989;482(2):252– 60. https://doi.org/10.1016/0006-8993(89)91188-8.</mixed-citation><mixed-citation xml:lang="en">McIntosh T.K., Vink R., Yamakami I., Faden A.I. Magnesium protects against neurological deficit after brain injury. Brain Res. 1989;482(2):252– 60. https://doi.org/10.1016/0006-8993(89)91188-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shepherd E., Salam R.A., Manhas D. et al. Antenatal magnesium sulphate and adverse neonatal outcomes: a systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002988. https://doi.org/10.1371/journal.pmed.1002988.</mixed-citation><mixed-citation xml:lang="en">Shepherd E., Salam R.A., Manhas D. et al. Antenatal magnesium sulphate and adverse neonatal outcomes: a systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002988. https://doi.org/10.1371/journal.pmed.1002988.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Vilchez G., Dai J., Lagos M., Sokol R.J. Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. J Matern Fetal Neonatal Med. 2018;31(2):178–83. https://doi.org/10.1080/14767058.2017.1279143/.</mixed-citation><mixed-citation xml:lang="en">Vilchez G., Dai J., Lagos M., Sokol R.J. Maternal side effects &amp; fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. J Matern Fetal Neonatal Med. 2018;31(2):178–83. https://doi.org/10.1080/14767058.2017.1279143/.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jayaram P.M., Mohan M.K., Farid I., Lindow S. Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. J Perinat Med. 2019;47(3):262–9. https://doi.org/10.1515/jpm-2018-0174.</mixed-citation><mixed-citation xml:lang="en">Jayaram P.M., Mohan M.K., Farid I., Lindow S. Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. J Perinat Med. 2019;47(3):262–9. https://doi.org/10.1515/jpm-2018-0174.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mittendorf R., Covert R., Boman J. et al. Is tocolytic magnesium sulphate associated with increased total pediatric mortality? Lancet. 1997;350(9090):1517–8. https://doi.org/10.1016/s0140-6736(97)24047-x.</mixed-citation><mixed-citation xml:lang="en">Mittendorf R., Covert R., Boman J. et al. Is tocolytic magnesium sulphate associated with increased total pediatric mortality? Lancet. 1997;350(9090):1517–8. https://doi.org/10.1016/s0140-6736(97)24047-x.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng X., Xue Y., Tian Q. et al. Effects and safety of magnesium sulfate on neuroprotection: a meta-analysis based on PRISMA guidelines. Medicine (Baltimore). 2016;95(1):e2451. https://doi.org/10.1097/MD.0000000000002451.</mixed-citation><mixed-citation xml:lang="en">Zeng X., Xue Y., Tian Q. et al. Effects and safety of magnesium sulfate on neuroprotection: a meta-analysis based on PRISMA guidelines. Medicine (Baltimore). 2016;95(1):e2451. https://doi.org/10.1097/MD.0000000000002451.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lecuyer M., Rubio M., Chollat C. et al. Experimental and clinical evidence of differential effects of magnesium sulfate on neuroprotection and angiogenesis in the fetal brain. Pharmacol Res Perspect. 2017;5(4):e00315. https://doi.org/10.1002/prp2.315.</mixed-citation><mixed-citation xml:lang="en">Lecuyer M., Rubio M., Chollat C. et al. Experimental and clinical evidence of differential effects of magnesium sulfate on neuroprotection and angiogenesis in the fetal brain. Pharmacol Res Perspect. 2017;5(4):e00315. https://doi.org/10.1002/prp2.315.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Millogo-Traoré T.F.D., Sawadogo O., Zongo-Kondé S.W. Evaluation of the fetal neuroprotection protocol with magnesium sulfate in a University Hospital in Burkina Faso. Open J Obstet Gynecol. 2022;12(10):1042–55. https://doi.org/10.4236/ojog.2022.1210087.</mixed-citation><mixed-citation xml:lang="en">Millogo-Traoré T.F.D., Sawadogo O., Zongo-Kondé S.W. Evaluation of the fetal neuroprotection protocol with magnesium sulfate in a University Hospital in Burkina Faso. Open J Obstet Gynecol. 2022;12(10):1042–55. https://doi.org/10.4236/ojog.2022.1210087.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Maged M.C., Weiner S.J.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal–Fetal Medicine Units Network (MFMU). Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a metaanalysis. Obstet Gynecol. 2009;114(2 Pt 1):354–64. https://doi.org/10.1097/AOG.0b013e3181ae98c2.</mixed-citation><mixed-citation xml:lang="en">Maged M.C., Weiner S.J.; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal–Fetal Medicine Units Network (MFMU). Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a metaanalysis. Obstet Gynecol. 2009;114(2 Pt 1):354–64. https://doi.org/10.1097/AOG.0b013e3181ae98c2.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
